Search Videos and More
News
Venturing Into New Treatment Territory for Myelofibrosis with a Fox Chase Investigator-Initiated Study
The study is a phase one, single-site, dose-escalation study for patients with myeloproliferative neoplasms unresponsive to any JAK2 inhibitor. It combines two oral medications, Pacritinib and Talazoparib, and is for transplant-ineligible patients.
News
Fox Chase Cancer Center’s Dr. Thomas J. Galloway Named a Fellow of the American Society for Radiation Oncology
Thomas J. Galloway, MD, Chief of the Division of Head and Neck Radiation Oncology at Fox Chase Cancer Center, was today named a Fellow of the American Society for Radiation Oncology (ASTRO) at its 66th Annual Meeting in Washington, D.C.
Document
Thoracic Malignancies: A Review of the Latest Evidence - AGENDA
Presented by Fox Chase Cancer Center, the Temple Lung Center, and the Temple Health Office for Continuing Medical Education
News
Fox Chase Cancer Center Researchers Show Adaptive Radiation Therapy Effectively Delivers Treatment For Liver Tumors in Study Presented at American Society For Radiation Oncology Meeting
Using CT-guided online adaptive radiation therapy (ART) for patients with liver tumors has proven to be an effective approach, according to findings presented today by Fox Chase Cancer Center researchers at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Washington, D.C.
News
Fox Chase Cancer Center and Lewis Katz School of Medicine at Temple University’s Dr. Eric Horwitz Elected to Executive Committee of Radiation Oncology Society
Eric Horwitz, MD, FABS, FASTRO, Chair of the Department of Radiation Oncology at Fox Chase Cancer Center and the Lewis Katz School of Medicine at Temple University, was elected to the Executive Committee of the Society of Chairs of Academic Radiation Oncology Programs (SCAROP), part of the American Society of Radiation Oncology (ASTRO).
News
Fox Chase Cancer Center Researchers Show Adaptive Radiation Therapy Delivers Treatment More Effectively in Study Presented at American Society for Radiation Oncology Meeting
Online adaptive radiation therapy (ART) delivered radiation more effectively than conventional radiation therapy in nearly half of patients, while also helping to decrease radiation dose to the esophagus in a majority of patients with thoracic spine tumors. That’s according to the results of a study presented today by Fox Chase Cancer Center researchers at the American Society for Radiation Oncology (ASTRO) Annual Meeting in Washington, D.C.Optimizing Treatment Strategies for Localized and Advanced Genitourinary Malignancies
The management of advanced kidney, bladder, and prostate cancer is rapidly evolving, and new robotic and minimally invasive surgical techniques are now available. This CME program is designed to address the challenges physicians face in treating these complex cases. Presented by the nationally recognized Fox Chase Cancer Center genitourinary oncology team—comprising experts in urology, radiation therapy, and medical oncology—this program will cover the latest advancements in surgical techniques, radiation therapies, and medical treatments for both localized and advanced bladder, kidney, and prostate cancers.
News
GASTROINTESTINAL CANCER PROGRAM
Comprehensive Care That Empowers Patients Through Risk Management, Prevention, Detection, Treatment, and Survivorship Services
News
MELANOMA AND SKIN CANCER PROGRAM
Comprehensive Care Empowers Patients Through Risk Assessment, Prevention, Detection, Treatment, and Survivorship
News
BREAST CANCER PROGRAM
Comprehensive Care That Empowers Patients Through Risk Management, Prevention, Detection, Treatment, and Survivorship Services
Course
Thoracic Malignancies: A Review of the Latest Evidence
Great therapeutic strides have been made for non-small cell lung cancer (NSCLC). In this CME, renowned specialists from multidisciplinary backgrounds will present innovative treatment modalities that include medical, surgical and radiation oncology, pulmonology, and radiologic options. The conference explores new care paradigms for early-stage disease, including the CheckMate-816 trial that combines immunotherapy with chemotherapy, and a discussion of eligibility through molecular and PD-L1 testing. Targeted therapies for EGFR mutations or ALK translocations, and EGFR-targeted therapy for locally advanced disease will also be discussed.
Course
Thoracic Malignancies: A Review of the Latest Evidence
Great therapeutic strides have been made for non-small cell lung cancer (NSCLC). In this CME, renowned specialists from multidisciplinary backgrounds will present innovative treatment modalities that include medical, surgical and radiation oncology, pulmonology, and radiologic options. The conference explores new care paradigms for early-stage disease, including the CheckMate-816 trial that combines immunotherapy with chemotherapy, and a discussion of eligibility through molecular and PD-L1 testing. Targeted therapies for EGFR mutations or ALK translocations, and EGFR-targeted therapy for locally advanced disease will also be discussed.